A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Clinical trial NCT05128825 · RECRUITING

Trial details

NCT number: NCT05128825
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Start date: 2022-02-17
Primary completion: 2026-12-01
Enrollment: 310

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.